The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 833-838

  Murrell, Jack ^a   Board, Ruth ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

Blood brain barrier; BRAF; Brain metastases; Dabrafenib; Ipilimumab; Melanoma; Vemurafenib

Indexed keywords

DABRAFENIB; DACARBAZINE; ELACRIDAR; FOTEMUSTINE; IPILIMUMAB; METHOTREXATE; PEPTIDE VACCINE; TEMOZOLOMIDE; VEMURAFENIB;

ADVANCED CANCER; ANTIGEN PRESENTATION; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CELL ACTIVATION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG PENETRATION; GLIOBLASTOMA; HUMAN; LIPID SOLUBILITY; LIPOPHILICITY; LONG TERM SURVIVAL; MELANOMA; MELANOMA METASTASIS; METASTATIC MELANOMA; MICROMETASTASIS; MOLECULAR WEIGHT; MORBIDITY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIOSENSITIVITY; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

BLOOD BRAIN BARRIER; BRAF; BRAIN METASTASES; DABRAFENIB; IPILIMUMAB; MELANOMA; VEMURAFENIB;

BRAIN NEOPLASMS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84883559224     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.004     Document Type: Review

References (62)

1. Skin cancer incidence statistics. [Internet] 2010. [Updated 2011 July 22; Cited 2013 Feb 25]. Available from http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/incidence/#source1.
2. Lemech C., Arkenau H.T. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012, 6:53-66.
3. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol 2012, 2012:647684.
4. Eggermont A.M., Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011, 47:2150-2157.
5. Jang S., Atkins M.B. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 2013, 14:e60-e69.
6. Melanoma statistics and outlook. [Internet] 2012. [Updated 2012 May 28; Cited 2013 Feb 25]. Available from http://www.cancerresearchuk.org/cancer-help/type/melanoma/treatment/melanoma-statistics-and-outlook#stage.
7. Marsden J.R., Newton-Bishop J.A., Burrows L., et al. Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg 2010, 63:1401-1419.
8. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
9. Finn L., Markovic S.N., Joseph R.W. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012, 10:23.
10. Colombino M., Capone M., Lissia A., et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-2529.
11. Jordan E.J., Kelly C.M. Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 2012, 13:2533-2543.
12. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
13. Rughani M.G., Gupta A., Middleton M.R. New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol 2013, 5:73-80.
14. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
15. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
16. Davies M.A., Liu P., McIntyre S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117:1687-1696.
17. Margolin K. Ipilimumab in a phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012, 1:1197-1199.
18. Sampson J.H., Carter J.H., Friedman A.H., Seigler H.F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20.
19. Skibber J.M., Soong S.J., Austin L., Balch C.M., Sawaya R.E. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996, 3:118-123.
20. Fonkem E., Uhlmann E.J., Floyd S.R., et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012, 12:1207-1215.
21. Fogarty G., Morton R.L., Vardy J., et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-a randomised phase III trial. BMC Cancer 2011, 11:142.
22. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33:583-590.
23. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
24. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
25. Smalley S.R., Schray M.F., Laws E.R., O'Fallon J.R. Adjuvant radiation therapy after surgical resection of solitary brain metastasis: association with pattern of failure and survival. Int J Radiat Oncol Biol Phys 1987, 13:1611-1616.
26. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
27. Lu-Emerson C., Eichler A.F. Brain metastases. Continuum (Minneap Minn) 2012, 18:295-311.
28. Hauswald H., Dittmar J.O., Habermehl D., et al. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol 2012, 7:130.
29. Selek U., Chang E.L., Hassenbusch S.J., et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004, 59:1097-1106.
30. Lwu S., Goetz P., Monsalves E., et al. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep 2013, 29:407-412.
31. Liew D.N., Kano H., Kondziolka D., et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011, 114:769-779.
32. Chang E.L., Selek U., Hassenbusch S.J., et al. Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005, 56:936-945. [discussion-45].
33. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
34. Kocher M., Soffietti R., Abacioglu U., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141.
35. Bhatnagar A.K., Kondziolka D., Lunsford L.D., Flickinger J.C. Recursive partitioning analysis of prognostic factors for patients with four or more intracranial metastases treated with radiosurgery. Technol Cancer Res Treat 2007, 6:153-160.
36. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01644591 Melanoma Gamma Knife; 2012 July 17 [cited 2013 Feb 6]. Available from http://clinicaltrials.gov/show/NCT01644591.
37. Fertil B., Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985, 11:1699-1707.
38. Patel P.M., Suciu S., Mortier L., et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011, 47:1476-1483.
39. Balakan O., Süner A., Yiǧiter R., Balakan T., Sirikçi A., Sevinç A. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med 2012, 51:2819-2823.
40. Rochet N.M., Kottschade L.A., Markovic S.N. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011, 365:2439-2441.
41. Rochet N.M., Dronca R.S., Kottschade L.A., et al. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 2012, 87:976-981.
42. Dummer R, Goldinger S, Turtschi C, et al. Open label pilot study of vemurafenib in previously treated metastatic melanoma (MM) patients (PTS) with symptomatic brain metastases (BM). European Society for Medical Oncology Congress, Vienna, Austria; 28 September - 2 October 2012.
43. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01378975, A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases. 2011June 21 [cited 2013 Feb 10]; [about 5 screens]. Available from: http://http://clinicaltrials.gov/show/NCT01378975.
44. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
45. Long G.V., Trefzer U., Davies M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
46. Mittapalli R.K., Vaidhyanathan S., Sane R., Elmquist W.F. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 2012, 342:33-40.
47. Wilhelm I., Molnár J., Fazakas C., Haskó J., Krizbai I.A. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci 2013, 14:1383-1411.
48. Wager T.T., Villalobos A., Verhoest P.R., Hou X., Shaffer C.L. Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opin Drug Discov 2011, 6:371-381.
49. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01781026, Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases; 2013 Jan 29 [cited 2013 Feb 6]. Available from http://www.clinicaltrials.gov/ct2/show/NCT01781026?term=vemurafenib+brain&rank=1.
50. Gillet J.P., Gottesman M.M. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010, 596:47-76.
51. Durmus S., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 2012, 9:3236-3245.
52. Lee J.M., Mehta U.N., Dsouza L.H., Guadagnolo B.A., Sanders D.L., Kim K.B. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013, 23:175-178.
53. van Vulpen M., Kal H.B., Taphoorn M.J., El-Sharouni S.Y. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 2002, 9:683-688.
54. Qin D., Ou G., Mo H., et al. Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys 2001, 51:959-962.
55. Hofmann M., Kiecker F., Wurm R., et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006, 76:59-64.
56. Weber J.S., Amin A., Minor D., Siegel J., Berman D., O'Day S.J. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011, 21:530-534.
57. Margolin K., Ernstoff M.S., Hamid O., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.
58. Di Giacomo A.M., Ascierto P.A., Pilla L., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012, 13:879-886.
59. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01703507 Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases; 2012 Oct 5 [cited 2013 Feb 6]. Available from http://clinicaltrials.gov/ct2/show/NCT01703507.
60. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
61. Du Four S., Wilgenhof S., Duerinck J., et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 2012, 48:3045-3051.
62. Carlino M.S., Fogarty G.B., Long G.V. Treatment of melanoma brain metastases: a new paradigm. Cancer J 2012, 18:208-212.